




NeuroBio



**A DISRUPTIVE APPROACH
TO
ALZHEIMER'S DISEASE**

AN INNOVATIVE TREATMENT PACKAGE




=

PERMANENT
PREVENTION
OF SYMPTOM
ONSET!

(A) & (B) DETECTION OF AD + (C) TREATMENT = PERMANENT PREVENTION OF SYMPTOMS!

(A)+(B): A PRE-SYMPTOMATIC DIAGNOSTIC PROGRAMME

- For the first 20 years (Stage I & II) AD is asymptomatic
- We need a read-out neurodegeneration is underway in otherwise seemingly healthy people
- TEST A: A home-based screen detecting dysfunction in primarily vulnerable cells (+/- mood disorder), a frequent but not exclusive prelude to AD
- TEST B: A quantative saliva test, GP administered, giving a diagnosis of rate of AD advancement



Nasal Swabs



TEST 'A'
(+/- Mood disorder)

Saliva



TEST 'B'
(MCI & AD)

1. Ethics approval being submitted
2. In-house optimization
3. Confirmation reflects CSF profile
4. Large scale testing in three colleges
5. Large scale testing psychiatric clinics



WELLINGTON COLLEGE




1. In house optimization with ELISA
2. Full clinical trial eg with Cedars Sinai
3. Regulatory approval
4. First application: to aid ongoing clinical trials

(C)NBP14: A NOVEL DRUG THERAPY




Medicines &
Healthcare products
Regulatory Agency


Better weight gain



AD MODEL MICE: TREATMENT INTRANASAL NBP14 TWICE WEEKLY FOR 14 WEEKS



Lower amyloid



Wild-type mice
explore novel (red)
object more than
familiar (blue)

Mice cannot
distinguish
familiar from
novel objects

Mice remember
if object familiar
(blue) vs novel
(red)

Brain amyloid (gold
blobs) significantly lower
in hippocampus

THE ASK & THE SPEND

INVESTMENT OF £20M

Biomarker Programme

DEVELOPMENT AND VALIDATION OF TWO TESTS, SCREEN AND DIAGNOSTIC- **£8M**

- From prototype to clinical trial and CA/CE Marking
- From validation diagnostic test to manufacturing
- Medical devices manufactured and approved

Prototype Therapeutic

INITIATE PHASE I TRIAL NBP14 - **£6M**

- From efficacy to IND submission
- GMP manufacturing
- Phase I clinical trial

Therapeutic Pipeline

SUPPORT AND PROGRESS PRODUCT PIPELINE - **£6M**

- IND studies for 3 different types of drug blocking T14
- Development animal model of AD
- Generate revenue from non-core assets



A DISRUPTIVE APPROACH TO NEURODEGENERATION

Susan.greenfield@neuro-bio.com

www.neuro-bio.com

Culham Campus, Oxford OX14 3DB, UK

- Confidentiality: The information contained herein is confidential and may not be reproduced, redistributed, or disclosed, in whole or in part, without the prior written consent from Neuro-Bio Limited. Unauthorised use, disclosure, or distribution of this presentation or its contents is prohibited and may be unlawful.
- This presentation is for informational purposes only and does not constitute an offer or solicitation to purchase or sell any securities or make any investment decisions. Any investment decisions must be made based on your own due diligence and consultation with your financial advisor.
- Past performance is not indicative of future results. Investments in securities, particularly those involving stocks, bonds, options, and other financial instruments, involve risk and may result in loss of principal. The value of investments can go up as well as down, and investors may not get back the full amount invested.
- This presentation may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in such statements. The information presented herein is believed to be reliable, but no representation or warranty, expressed or implied, is made regarding its accuracy or completeness.
- This presentation does not constitute legal, tax, or accounting advice. Investors should consult their own advisors regarding the potential legal, tax, and accounting implications of investing in securities.
- Investing in private placements, venture capital, or early-stage companies involves a high degree of risk, including illiquidity, lack of diversification, and loss of investment. Investors should be prepared to bear the risk of loss.
- The views and opinions expressed in this presentation are those of the author and do not necessarily reflect the views of the company or its affiliates.